商品编号


AG-40T-0363-R500



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

500 ?l

商品信息


More Information



Product Details



Synonyms

Small Ubiquitin-related Modifier 1; GAP-modifying Protein 1; SMT3C, SMT3H3, UBL1; Sentrin; Ubiquitin-homology Domain Protein PIC1



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human SUMO1 (Accession Nr. P63165) coupled to agarose.



Crossreactivity

Human



Label/Conjugates

Agarose



Formulation

Liquid. In HEPES, NaCl and 20% Ethanol.



Other Product Data


Use:
Covalently coupled to agarose beads via primary amines allowing for a fully functional C-terminus. Useful for affinity binding of SUMO-1 activating enzyme, SUMO conjugating E2 enzyme Ubch9, SUMO-1 ligases, SUMO C-terminal hydrolases, and other proteins or enzymes that have an affinity for SUMO-1. Equilibrate resin by washing with 5-10ml desired start buffer. Binding and elution of material is dependent on individual experimental conditions.



Declaration

Manufactured by Boston Biochem



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

+4°C



Handling Advice

Do not freeze.



Use/St
ABI
lity

Stable for at least 3 months after receipt when stored at +4°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Small Ubiquitin-like Modifier 1 (SUMO1), also known as Sentrin, UBL1, and SMT3C, is synthesized as a 101 amino acid (aa) propeptide with a predicted molecular weight of 11.5 kDa. Human SUMO1 is the most unique of the four identified SUMO proteins and shares only 44%, 47%, and 41% aa sequence identity with SUMO2, SUMO3, and SUMO4, respectively. In contrast, human SUMO1 shares 100% aa sequence identity with the mouse ortholog. SUMOs are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. All SUMO proteins share a conserved ubiquitin domain and a C-terminal diglycine cleavage/attachment site. Following cleavage of a four aa C-terminal prosegment, the C-terminal glycine residue of SUMO1 is enzymatically attached to a lysine residue on a target protein. In humans, SUMO1 is conjugated to a variety of molecules in the presence of the SAE1/UBA2 SUMO-activating (E1) enzyme and the UBE2I/Ubc9 SUMO-conjugating (E2) enzyme. In yeast, the SUMO-activating (E1) enzyme is Aos1/Uba2p. SUMOylation can occur without the requirement of a specific SUMO ligase (E3), where SUMO1 is transferred directly from UBE2I/Ubc9 to specific substrates. In Alzheimer's disease models SUMO1 has been shown to influence the generation of amyloid-β peptide by promoting the accumulation of BACE-1. Covalent modification of PTEN by SUMO1 is thought to regulate tum
Origen
esis by retaining PTEN at the plasma membrane, an effect that suppresses PI 3-Kinase/Akt-dependent tumor growth.